Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bermekimab in moderate to severe atopic dermatitis
NCT04021862Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bermekimab in atopic dermatitis (AD), sponsored by Janssen Pharmaceutical. Started Oct 2019; status: completed.
02
Drugs
bermekimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04021862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021862.